StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) stock

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$2.41+0.13 (+5.70%)

Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%

enGene Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

enGene Therapeutics's total debt was $25.16M at Jul 31, 2026. For fiscal 2025 it was $15.32M, down 31.8% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Oct 31, 2025$15.32M-31.8%
FY2024Oct 31, 2024$22.47M+143.8%
FY2023Oct 31, 2023$9.22M-4.5%
FY2022Oct 31, 2022$9.65M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jul 31, 2026$25.16M+42.1%
Q2 FY2026CQ1 2026Apr 30, 2026$24.91M+24.4%
Q1 FY2026CQ4 2025Jan 31, 2026$24.74M+14.0%
Q4 FY2025CQ3 2025Oct 31, 2025$15.32M-31.8%
Q3 FY2025CQ2 2025Jul 31, 2025$17.71M-18.1%
Q2 FY2025CQ1 2025Apr 30, 2025$20.02M-11.9%
Q1 FY2025CQ4 2024Jan 31, 2025$21.70M-3.7%
Q4 FY2024CQ3 2024Oct 31, 2024$22.47M+143.8%
Q3 FY2024CQ2 2024Jul 31, 2024$21.61M+124.0%
Q2 FY2024CQ1 2024Apr 30, 2024$22.73M–
Q1 FY2024CQ4 2023Jan 31, 2024$22.53M–
Q4 FY2023CQ3 2023Oct 31, 2023$9.22M–
Q4 FY2022CQ3 2022Oct 31, 2022$9.65M–

More enGene Therapeutics figures

See a number that looks wrong?